2023

Dr. Riera-Mestre, elected editor of the most prestigious journal in the field of minority diseases

The coordinator of the IDIBELL Systemic, Vascular and Aging Diseases group will be globally responsible, together with two other editors, for the section on Rare Cardiovascular Diseases of the Orphanet Journal of Rare Diseases.

Dr. Riera-Mestre, elected editor of the most prestigious journal in the field of minority diseases Read More »

The Catalan Institute of Oncology and IDIBELL lead the PIECES Project aimed at implementing interventions in the field of cancer prevention

Funded by the European Union, the project aims to develop, evaluate and disseminate a methodological implementation framework for cancer known as the ‘Integrated Implementation Kit’ in six risk factors, such as tobacco, alcohol, ‘sun exposure, the human papilloma virus, nutrition and physical activity.

The Catalan Institute of Oncology and IDIBELL lead the PIECES Project aimed at implementing interventions in the field of cancer prevention Read More »

A new endoscopy study from Bellvitge published in the main scientific journal of the digestive specialty

The American Journal of Gastrointestinal Endoscopy published a multicenter study on the treatment of gastrointestinal subepithelial tumors led by the Bellvitge Biomedical Research Institute (IDIBELL) and the Digestive Endoscopy Unit of the Bellvitge University Hospital (HUB).

A new endoscopy study from Bellvitge published in the main scientific journal of the digestive specialty Read More »

The omic sciences to advance in precision medicine are the focus of the NeuroDebate 2023 conference

This past June 9 and 10, NeuroDebate took place, a conference promoted by the Bellvitge University Hospital (HUB), the Bellvitge Biomedical Research Institute (IDIBELL) and the University of Barcelona.

The omic sciences to advance in precision medicine are the focus of the NeuroDebate 2023 conference Read More »

A new paradigm in the treatment of patients with diffuse large B-cell lymphoma, one of the most aggressive blood cancers

It is the first treatment in the last 30 years that represents a relative improvement of 38% in the overall survival of patients compared to standard treatment. The results of Phase III study ZUMA-7 show that this new treatment with Yescarta (axicabtagén ciloleucel, known as axicel) reduces the risk of death by 27.4%.

A new paradigm in the treatment of patients with diffuse large B-cell lymphoma, one of the most aggressive blood cancers Read More »

Advances in the approach to multiple sclerosis, within reach of patients on World MS Day

The Neurological Diseases and Neurogenetics research group of the Bellvitge Biomedical Research Institute (IDIBELL) and the Multiple Sclerosis Unit of the Neurology Service of the HUB have co-organized this day to explain the new advances achieved in the approach and search of the disease and to give voice to patients.

Advances in the approach to multiple sclerosis, within reach of patients on World MS Day Read More »

IDIBELL and the University of Iowa developed a new molecule for targeted treatment against cancer

It is an aptamer, a small nucleic acid molecule that specifically recognizes a receptor highly expressed in tumor cells of breast cancer, sarcoma, melanoma, and colon cancer, among others. The new molecule could be linked to cancer treatments and used as a platform for localized drug delivery that reduces side effects.

IDIBELL and the University of Iowa developed a new molecule for targeted treatment against cancer Read More »

Scroll to Top